Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1302426

registered interest
date	15/03/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Phenylketonuria: Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make urgent representations to NICE to ensure that Sapropterin (Kuvan) can be made available for Phenylketonuria (a) on the basis of clinical need and (b) not restricted to people under the age of 18 years.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	169047
answer	answer is ministerial correction date of answer 23/03/2021 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing evidence-based guidance for the National Health Service on whether medicines represent a clinical and cost-effective use of resources. NICE is currently developing recommendations for the NHS on the use of sapropterin for the treatment of phenylketonuria and it would not be appropriate for Ministers to intervene in the development of its guidance.</p><p>NICE published draft guidance on the use of sapropterin for consultation on 25 February 2021 which recommends its use for children under 18 up to a dose of 10mg/kg. NICE will carefully consider the comments received in developing its final recommendations. NICE expects to publish its final guidance on sapropterin in June 2021.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 169048 question first answered 23/03/2021 12:44:40 answering member 4380 label Biography information for Jo Churchill
tabling member	4769 label Biography information for Daisy Cooper

1301564

registered interest
date	10/03/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Phenylketonuria: Sapropterin
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of NICE draft guidance on using Sapropterin for treating phenylketonuria, published on 25 February; and what plans they have to meet with the authors of that guidance.
tabling member printed	Lord Austin of Dudley
uin	HL14077
answer	answer is ministerial correction date of answer 17/03/2021 answer text <p>The National Institute for Health and Care Excellence is an independent body and is responsible for assessing new medicines and treatments in accordance with its existing methods and processes. It would not be appropriate for Ministers to intervene in the development of their recommendations.</p> answering member printed Lord Bethell question first answered 17/03/2021 16:37:40 answering member 4708 label Biography information for Lord Bethell
tabling member	1511 label Biography information for Lord Austin of Dudley

1231941

registered interest
date	07/09/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Phenylketonuria: Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with NICE on the appraisal of Kuvan as a treatment for phenylketonuria.
tabling member constituency	Darlington
tabling member printed	Peter Gibson
uin	86169
answer	answer is ministerial correction date of answer 21/09/2020 answer text <p>Departmental Ministers and officials regularly discuss a range of matters with colleagues in the National Institute for Health and Care Excellence, including the availability of medicines for the treatment of a number of conditions.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 21/09/2020 16:23:26 answering member 4380 label Biography information for Jo Churchill
tabling member	4754 label Biography information for Peter Gibson

1183284

registered interest
date	06/03/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Phenylketonuria: Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to make the drug Kuvan for people with phenylketonuria available on the NHS.
tabling member constituency	Coventry South
tabling member printed	Zarah Sultana
uin	26187
answer	answer is ministerial correction date of answer 16/03/2020 answer text <p>The National Institute for Health and Care Excellence (NICE) has been asked to develop recommendations for the National Health Service on the use of Kuvan for the treatment of phenylketonuria through its technology appraisal programme. NHS commissioners are legally required to fund medicines recommended in NICE technology appraisal guidance.</p><p>NICE’s appraisal had been suspended as the manufacturer of Kuvan, BioMarin, had withdrawn from the process. However, BioMarin has now agreed to re-engage in the appraisal and NICE will now aim to publish guidance on Kuvan as soon as possible. Further information on the appraisal is available on NICE’s website at the following link:</p><p><a href="https://www.nice.org.uk/guidance/indevelopment/gid-ta10378" target="_blank">https://www.nice.org.uk/guidance/indevelopment/gid-ta10378</a></p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 16/03/2020 15:43:31 answering member 4380 label Biography information for Jo Churchill
tabling member	4786 label Biography information for Zarah Sultana

1124974

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Phenylketonuria: Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the NICE appraisal of Kuvan will consider the increased prevalence of neuropsychiatric comorbidities in adults with phenylketonuria.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	251357
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>In developing its recommendations on Kuvan, the National Institute for Health and Care Excellence (NICE) will consider all the health-related costs and benefits associated with the treatment in accordance with its published methods and processes and the scope for the appraisal that has been developed in consultation with stakeholders; potentially including any costs from National Health Service funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251358 question first answered 15/05/2019 16:31:51 answering member 4455 label Biography information for Seema Kennedy
tabling member	4603 label Biography information for Preet Kaur Gill